I-Mab announces accelerated givastomig Phase 1b study progress

I-Mab (IMAB) announced that enrollment has been completed ahead of schedule in the first dose expansion cohort in the Phase 1b givastomig combination study, with continued momentum in the second dose expansion cohort. The Phase 1b study is evaluating givastomig, a potential best-in-class, Claudin 18.2 x 4-1BB bispecific antibody, targeting CLDN18.2-expressing tumor cells for the treatment of gastric cancer in the first-line setting. The Phase 1b program includes a dose escalation study and a dose expansion study. Enrollment in the dose escalation study is complete, and topline data are expected in the second half of 2025.